Description of Patients With Type 1 Diabetes Treated With Teplizumab

CompletedOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

August 5, 2025

Study Completion Date

August 5, 2025

Conditions
Type 1 Diabetes
Interventions
DRUG

Teplizumab

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

Trial Locations (27)

10016

Hassenfeld Children's Hospital at NYU Langone, New York

10032

Morgan Stanley Children's Hospital, New York

10306

Ten's Medical PC, Staten Island

13210

SUNY Upstate Medical University PARENT, Syracuse

20010

Children's National Medical Center, Washington D.C.

30318

Atlanta Diabetes Associates, Atlanta

30329

Childrens Healthcare of Atlanta, Atlanta

32960

Doctor's Clinic, Vero Beach

33136

University of Miami Medical Center, Miami

33612

USF Diabetes Center, Tampa

37232

Vanderbilt University Medical Center, Nashville

38133

AM Diabetes & Endocrinology Center, Bartlett

40202

University of Louisville, Louisville

46032

Riley Hospital for Children, Carmel

52621

Sheba Medical Center, Ramat Gan

58122

Sanford Research/USD, Fargo

72202

Arkansas Children's Hospital Research Institute, Little Rock

75390

University of Texas Southwestern Medical Center, Dallas

80045

Barbara Davis Center For Childhood Diabetes, Aurora

84093

Diabetes and Endocrine Treatment Specialists, Sandy City

84108

University of Utah Hospitals & Clinics, Salt Lake City

94158

University of California, San Francisco, San Francisco

4920235

Schneider Children's Medical Center, Petah Tikva

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

02115

Boston Children's Hospital Division of Endocrinology, Boston

07960

Atlantic Health, Morristown

79902-4646

El Paso Medical Research Institute, El Paso

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY